Similar to the group, the core company's revenues were up 7% as well to

EUR 521.3m, while its profit was 10% lower at EUR 82.9m, according to

unaudited data presented today.

The group's operating profit reached

EUR 117.1m between January and June, down 5% compared to the same period

last year. The company's operating profit was down as well, by 13% to EUR

102.3m.

The group generated 92% of its revenues abroad, while the

share of revenue from foreign markets is even higher for the core company,

which saw 94% of revenue generated abroad.

Nonetheless, the drug

maker saw revenues increase in some markets, most notably in east Europe,

where the sales were up by as much as 25%. This region is also Krka's

biggest market - some 30% of its products are sold there.

In the

first half of the year, the group spent EUR 58m on investments: EUR 26.4m

was invested by the company and EUR 31.6m by its subsidiaries.

The

data also shows that the number of Krka employees has increased by 3% since

January to a total of 9,203 at the end of June.